The stock has a 36-month beta value of 1.06. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ERAS is 163.45M, and at present, short sellers hold a 20.72% of that float. On March 14, 2025, the average trading volume of ERAS was 1.36M shares.
ERAS) stock’s latest price update
Erasca Inc (NASDAQ: ERAS) has seen a decline in its stock price by -3.92 in relation to its previous close of 1.53. However, the company has experienced a 3.52% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-31 that SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings.
ERAS’s Market Performance
Erasca Inc (ERAS) has seen a 3.52% rise in stock performance for the week, with a -6.96% decline in the past month and a -50.67% plunge in the past quarter. The volatility ratio for the week is 9.19%, and the volatility levels for the past 30 days are at 8.96% for ERAS. The simple moving average for the past 20 days is 1.62% for ERAS’s stock, with a -40.78% simple moving average for the past 200 days.
Analysts’ Opinion of ERAS
Many brokerage firms have already submitted their reports for ERAS stocks, with Jefferies repeating the rating for ERAS by listing it as a “Buy.” The predicted price for ERAS in the upcoming period, according to Jefferies is $6 based on the research report published on November 18, 2024 of the previous year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see ERAS reach a price target of $8. The rating they have provided for ERAS stocks is “Overweight” according to the report published on March 11th, 2024.
BofA Securities gave a rating of “Neutral” to ERAS, setting the target price at $6 in the report published on January 05th of the previous year.
ERAS Trading at -18.60% from the 50-Day Moving Average
After a stumble in the market that brought ERAS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.39% of loss for the given period.
Volatility was left at 8.96%, however, over the last 30 days, the volatility rate increased by 9.19%, as shares sank -6.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.13% lower at present.
During the last 5 trading sessions, ERAS rose by +3.52%, which changed the moving average for the period of 200-days by -43.24% in comparison to the 20-day moving average, which settled at $1.4465. In addition, Erasca Inc saw -41.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ERAS starting from Erasca Foundation, who proposed sale 8,333 shares at the price of $1.53 back on Feb 18 ’25. After this action, Erasca Foundation now owns shares of Erasca Inc, valued at $12,752 using the latest closing price.
Erasca Foundation, the Affiliate of Erasca Inc, proposed sale 8,333 shares at $1.94 during a trade that took place back on Jan 15 ’25, which means that Erasca Foundation is holding shares at $16,183 based on the most recent closing price.
Stock Fundamentals for ERAS
Current profitability levels for the company are sitting at:
- -27.82 for the present operating margin
- 0.46 for the gross margin
The net margin for Erasca Inc stands at -28.52. The total capital return value is set at -0.31. Equity return is now at value -40.33, with -33.56 for asset returns.
Based on Erasca Inc (ERAS), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -2.07. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -40.58.
Currently, EBITDA for the company is -121.31 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 71.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.00.
Conclusion
To sum up, Erasca Inc (ERAS) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
